Nanovibronix (NASDAQ:FEED) Upgraded to Sell at Wall Street Zen

Nanovibronix (NASDAQ:FEED) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a report on Friday, April 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nanovibronix presently has a consensus rating of “Sell”.

Nanovibronix Price Performance

Nanovibronix stock traded down $0.01 during mid-day trading on Friday, reaching $0.53. The stock had a trading volume of 523,274 shares, compared to its average volume of 362,778. The stock has a market cap of $3.22 million, a price-to-earnings ratio of -0.06 and a beta of 1.56. Nanovibronix has a fifty-two week low of $0.42 and a fifty-two week high of $17.40. The company has a 50-day simple moving average of $0.84.

Nanovibronix (NASDAQ:FEED) last issued its earnings results on Monday, May 18th. The company reported ($6.88) earnings per share for the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.The firm had revenue of $0.65 million for the quarter.

Insider Buying and Selling at Nanovibronix

In related news, insider Christian Michael Glibert sold 210,000 shares of Nanovibronix stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $0.69, for a total transaction of $144,900.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.40% of the stock is owned by corporate insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.